Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated March 13, 2025, reports on share repurchase activities for the period from February 1, 2025, to February 28, 2025. The filing is submitted pursuant to Rule 13a-16 of the Securities Exchange Act of 1934 and complies with Article 24-6 of the Financial Instruments and Exchange Act of Japan.
Key Financial Metrics: Share Repurchase Activity
The filing details a specific share repurchase program approved by the Board of Directors on January 30, 2025, with a total authorized amount of 100,000,000,000 JPY and a target of 28,500,000 shares. The repurchase period is set from February 17, 2025, to May 31, 2025.
| Metric | Value |
|---|---|
| Total Shares Repurchased (Feb 2025) | 5,395,400 |
| Total Amount Spent (Feb 2025) | 22,798,222,000 JPY |
| Program Progress (Shares) | 18.93% |
| Program Progress (Amount) | 22.80% |
| Treasury Shares Held (as of Feb 28, 2025) | 55,886,006 |
| Total Issued Shares | 1,590,949,609 |
Material Changes and Transaction Details
During the reporting month, Takeda executed repurchases on six trading days (February 19, 20, 21, 25, 26, and 27, 2025). The company purchased 752,200 shares on five of these days and 817,200 shares on February 27, 2025. The average price per share varied slightly across transactions, ranging approximately between 4,199 JPY and 4,291 JPY based on the total amounts and share counts provided.
Management Commentary and Risks
The filing indicates that the repurchases were conducted via open-market transactions through a trust bank. No material risks, contingencies, or unusual items were disclosed in this specific report. The filing does not contain forward-looking guidance, revenue projections, or profit margins, as it is strictly a regulatory disclosure of capital return activities.
Investor Verification Checklist
- Verify the remaining authorized amount for the current repurchase program (approx. 77.2 billion JPY).
- Confirm the total number of treasury shares held (55,886,006) against the company's latest balance sheet to assess impact on earnings per share.
- Monitor the execution pace against the May 31, 2025, deadline for the current Board resolution.
- Note that treasury share counts exclude shares held by ESOP and BIP trust accounts.